Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Lepu Biopharma's MRG-003?
MRG-003 is a monoclonal antibody conjugated commercialized by Lepu Biopharma, with a leading Phase II program in Adenocarcinoma Of The...
MRG-003 by Shanghai Miracogen for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
MRG-003 by Shanghai Miracogen for Non-Small Cell Lung Cancer: Likelihood of Approval
MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Non-Small Cell Lung Cancer. According to...
MRG-003 by Shanghai Miracogen for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
MRG-003 is under clinical development by Shanghai Miracogen and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...